Key result
CRUCIAL study evaluates cerebral and cardiac microvascular rarefaction in HFpEF and VCI.
Why the study?
Microvascular rarefaction appears to be an important mechanism in small blood vessel-related disorders such as VCI and HFpEF, but non-invasive tools to quantify microvascular health and rarefaction across both organs need investigation.
Does microvascular rarefaction quantified by advanced brain and cardiac MRI and non-invasive surrogate biomarkers correlate with cognitive and cardiac disease severity in patients with vascular cognitive impairment and heart failure with preserved ejection fraction?
Cohort (n=395)
Yes
Does microvascular rarefaction quantified by advanced brain and cardiac MRI and non-invasive surrogate biomarkers correlate with cognitive and cardiac disease severity in patients with vascular cognitive impairment and heart failure with preserved ejection fraction?
This study protocol establishes a multicenter multimodal imaging and biomarker framework to investigate whether microvascular rarefaction is a shared pathophysiological mechanism and early diagnostic target in vascular cognitive impairment and HFpEF.
Answers are grounded in this paper and cite their sources.
Protocol establishes multimodal MRI-biomarker framework for microvascular rarefaction in VCI and HFpEF; leaves open correlation with disease severity.
INTRODUCTION: Microvascular rarefaction, the functional reduction in perfused microvessels and structural reduction of microvascular density, seems to be an important mechanism in the pathophysiology of small blood vessel-related disorders including vascular cognitive impairment (VCI) due to cerebral small vessel disease and heart failure with preserved ejection fraction (HFpEF). Both diseases share common risk factors including hypertension, diabetes mellitus, obesity, and ageing; in turn, these comorbidities are associated with microvascular rarefaction. Our consortium aims to investigate novel non-invasive tools to quantify microvascular health and rarefaction in both organs, as well as surrogate biomarkers for cerebral and/or cardiac rarefaction (via sublingual capillary health, vascular density of the retina, and RNA content of circulating extracellular vesicles), and to determine whether microvascular density relates to disease severity. METHODS: The clinical research program of CRUCIAL consists of four observational cohort studies. We aim to recruit 75 VCI patients, 60 HFpEF patients, 60 patients with severe aortic stenosis (AS) undergoing surgical aortic valve replacement as a pressure overload HFpEF model, and 200 elderly participants with mixed comorbidities to serve as controls. Data collected will include medical history, physical examination, cognitive testing, advanced brain and cardiac MRI, ECG, echocardiography, sublingual capillary health, optical coherence tomography angiography (OCTa), extracellular vesicles RNA analysis, and myocardial remodelling-related serum biomarkers. The AS cohort undergoing surgery will also have myocardial biopsy for histological microvascular assessment. DISCUSSION: CRUCIAL will examine the pathophysiological role of microvascular rarefaction in VCI and HFpEF using advanced brain and cardiac MRI techniques. Furthermore, we will investigate surrogate biomarkers for non-invasive, faster, easier, and cheaper assessment of microvascular density since these are more likely to be disseminated into widespread clinical practice. If microvascular rarefaction is an early marker of developing small vessel diseases, then measuring rarefaction may allow preclinical diagnosis, with implications for screening, risk stratification, and prevention. Further knowledge of the relevance of microvascular rarefaction and its underlying mechanisms may provide new avenues for research and therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Dinther et al. (2023) conducted a cohort in Vascular cognitive impairment (VCI), heart failure with preserved ejection fraction (HFpEF), and severe aortic stenosis (AS) (n=395). Microvascular rarefaction and dysfunction assessed via multimodal brain and cardiac MRI, sublingual videomicroscopy (GlycoCheck), retinal OCT angiography, and endothelial-derived extracellular vesicles vs. 200 elderly participants with mixed comorbidities serving as controls (AGE cohort) was evaluated on Correlation between advanced MRI measures of microvascular function/density in the brain and heart and disease severity (cognitive function, structural MRI markers, NYHA class, and HFpEF markers), and histological capillary density on myocardial biopsy. The CRUCIAL study protocol outlines a multicenter prospective cohort study of 395 participants to evaluate cerebral and cardiac microvascular rarefaction in VCI and HFpEF.
Synapse has enriched 10 related papers. Consider them for comparative context: